comparemela.com
Home
Live Updates
First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients : comparemela.com
First Patient Dosed in Pivotal Phase III Study of TLX591-CDx (Illuccix®) for Prostate Cancer Imaging in Chinese Patients
/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in China in the pivotal Phase...
Related Keywords
United Kingdom ,
Belgium ,
Canada ,
Melbourne ,
Victoria ,
Australia ,
Japan ,
Dingwei ,
Fujian ,
China ,
United States ,
Switzerland ,
Chinese ,
Australian ,
Telix Asia Pacific ,
Cdx Illuccix ,
Kyahn Williamson ,
Corporate Communications ,
Health Canada ,
Telix Pharmaceuticals ,
Zhongnan Hospital Of Wuhan University ,
Telix Pharmaceuticals Limited Disclosure Committee ,
European Union ,
Prnewswire Telix Pharmaceuticals Limited ,
Drug Administration ,
Australian Therapeutic Goods Administration ,
Group Limited Grand Pharma ,
Linkedin ,
Australian Securities Exchange ,
Pharmaceuticals Limited ,
United States Food ,
Greater China ,
Grand Pharmaceutical Group Limited ,
Grand Pharma ,
Regional Medical Director ,
Zhongnan Hospital ,
Wuhan University ,
Prostate Cancer ,
Asia Pacific ,
Telix Pharmaceuticals Limited ,
Biotechnology ,
Health Care Amp Hospitals ,
Pharmaceuticals ,
Medical Pharmaceuticals ,
Clinical Trials Amp Medical Discoveries ,
Surveys ,
Olls And Research ,
comparemela.com © 2020. All Rights Reserved.